Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platfor...
2023-08-11 10:41:32 ET Senti Biosciences press release ( NASDAQ: SNTI ): Q2 GAAP EPS of -$0.42. Revenue of $0.93M (-31.1% Y/Y). For further details see: Senti Biosciences GAAP EPS of -$0.42, revenue of $0.93M
– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on track for 2H 2023 – – Cash, cash equivalents, and sho...
– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction anticipated to extend Senti Bio’s cash runway into Q4 2024 –...
SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced multiple presentations highligh...
2023-05-10 13:23:53 ET Senti Biosciences press release ( NASDAQ: SNTI ): Q1 GAAP EPS of -$0.42 beats by $0.13 . Revenue of $1.29M beats by $0.29M . For further details see: Senti Biosciences GAAP EPS of -$0.42 beats by $0.13, revenue of $1.29M beats by $0...
– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating th...
- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology - - New preclinical data demonstrate ongoing progress from collaborations with BlueRock and Spark - SOUTH SAN FRANCISCO, C...
2023-04-25 09:04:56 ET TRACON Pharmaceuticals ( TCON ) -51% after I-Mab gets favorable ruling in arbitration. Appreciate Holdings ( SFR ) -26% . First Republic Bank ( FRC ) -22% after Q1 earning release . Netcapital ( NCPL ) -22% . T...
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 – – Additional data presented on SENTI-301A and crIL-15 support Senti’s development of gene circuit enhanced CA...
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
Senti Biosciences Inc. Website:
2024-07-18 09:02:04 ET SNTI (SNTI) announced stock split at a ratio of 1-for-10 on 2024-07-18 ... Full story available on KlickAnalytics.com
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors h...
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...